Pacer Advisors
NKTR icon

Pacer Advisors’s Nektar Therapeutics NKTR Stock Holding History

Pacer Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,913
Closed -$515K – 2212
2021
Q3 		$515K Buy
1,913
+633
+49% +$152K 0.01% 1130
2021
Q2 		$329K Sell
1,280
-15
-1% -$4.15K ﹤0.01% 1247
2021
Q1 		$389K Sell
1,295
-32
-2% -$9.96K 0.01% 1145
2020
Q4 		$338K Sell
1,327
-1,545
-54% -$399K 0.01% 1110
2020
Q3 		$715K Buy
+2,872
New +$903K 0.02% 857
2020
Q1 		– Sell
-3,982
Closed -$1.29M – 957
2019
Q4 		$1.29M Buy
3,982
+1,831
+85% +$531K 0.06% 468
2019
Q3 		$588K Buy
2,151
+677
+46% +$248K 0.01% 963
2019
Q2 		$787K Buy
1,474
+441
+43% +$221K 0.02% 885
2019
Q1 		$521K Sell
1,033
-760
-42% -$450K 0.01% 568
2018
Q4 		$884K Buy
1,793
+236
+15% +$142K 0.03% 97
2018
Q3 		$1.42M Buy
1,557
+1,064
+216% +$908K 0.05% 479
2018
Q2 		$361K Buy
493
+83
+20% +$95.7K 0.02% 972
2018
Q1 		$654K Buy
+410
New +$528K 0.04% 647

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Pacer Advisors's NKTR Position: Q4 2021 in Review

Pacer Advisors sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 1,913 shares — an estimated $515K sold.

Pacer Advisors first reported a position in NKTR in Q1 2018 and held it in 13 quarters. The position peaked at $1.42M in Q3 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

  • Pacer Advisors reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Pacer Advisors sold 1,913 Nektar Therapeutics shares in Q4 2021, an estimated $515K.
  • Pacer Advisors first reported a position in Nektar Therapeutics in Q1 2018 and held it in 13 quarters.
  • Pacer Advisors's Nektar Therapeutics position peaked at $1.42M in Q3 2018.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Pacer Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.